Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old.

Leukemia Research
Simrit ParmarMartin S Tallman

Abstract

The prognosis for patients with relapsed/refractory AML, secondary leukemia and AML in older adults is extremely poor. An appealing alternative approach to intensive cytotoxic chemotherapy is to induce apoptosis with a novel agent. There is in vitro evidence that arsenic trioxide (ATO) has anti-proliferative and pro-apoptotic effects on myeloid leukemia cell lines. To evaluate efficacy and toxicities of ATO, we conducted a phase II trial including subjects with relapsed/refractory or secondary AML or age > or = 65 years with de novo disease. Eleven subjects were entered with a median age of 77 years (56-90) and a median total dose of ATO of 415.55 mg (91.5-793) with a daily dose of 0.25 mg/kg. Median survival following the first dose of ATO was 2.25 months (0.4-19). Myelosuppression was the major adverse effect, most likely due to disease progression rather than drug-related. All subjects had progressive disease. There was no direct treatment-related mortality. Based on this study, we do not recommend single agent ATO as a treatment option for AML.

References

Jul 1, 1991·British Journal of Haematology·J M BennettC Sultan
Aug 1, 1988·The American Journal of the Medical Sciences·D A Sears
Apr 15, 1997·Proceedings of the National Academy of Sciences of the United States of America·J ZhuH de Thé
Jun 17, 1998·Genes & Development·V Cryns, J Yuan
Aug 28, 1998·Science·A Ashkenazi, V M Dixit
Aug 28, 1998·Science·N A Thornberry, Y Lazebnik
Sep 12, 1998·Science·J M Adams, S Cory
Nov 5, 1998·The New England Journal of Medicine·S L SoignetR P Warrell
Sep 29, 1999·Cancer Chemotherapy and Pharmacology·S L SoignetR P Warrell
Mar 18, 2000·Leukemia & Lymphoma·Y AkaoY Nakagawa
Mar 22, 2001·British Journal of Haematology·T Bachleitner-HofmannH Gisslinger
May 23, 2002·Chemical Research in Toxicology·Teruaki SakuraiMichael P Waalkes

❮ Previous
Next ❯

Citations

May 12, 2005·Blood Reviews·Daniel V T Catenacci, Gary J Schiller
Feb 27, 2008·Acta Pharmacologica Sinica·Wing-Yan Au, Yok-Lam Kwong
Nov 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Meir WetzlerHeinz Baumann
Apr 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Meir WetzlerWilliam J Jusko
Aug 12, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mustafa BenekliMeir Wetzler
Oct 25, 2008·Leukemia & Lymphoma·Emma Coe, Aaron D Schimmer
Jun 24, 2008·Expert Opinion on Pharmacotherapy·Mark R Litzow
Nov 3, 2010·Critical Reviews in Oncology/hematology·Antonio Rodriguez-ArizaNuria Barbarroja
Jan 19, 2007·Clinical Lymphoma & Myeloma·James R Berenson, Howard S Yeh
Dec 29, 2015·Blood Reviews·Pallawi TorkaElizabeth A Griffiths
Jul 13, 2007·Cancer Treatment Reviews·Pierre J Dilda, Philip J Hogg
Jul 6, 2004·Leukemia Research·Srdan Verstovsek, Zeev Estrov
Apr 25, 2008·Blood Reviews·Chad M Craig, Gary J Schiller
Feb 5, 2013·Cancer Biology & Therapy·John P GalvinLeonidas C Platanias
Apr 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dan Douer, Martin S Tallman
Jun 20, 2006·Hematological Oncology·Srdan VerstovsekHagop Kantarjian
Mar 13, 2020·Metallomics : Integrated Biometal Science·Qian Qian WangHua Naranmandura
Mar 7, 2007·Expert Review of Anticancer Therapy·Gail J Roboz
Apr 23, 2021·Cancer & Metabolism·Svetlana B PaninaNatalia V Kirienko
Jul 3, 2021·Biomedicines·Minyoung YounKathleen M Sakamoto
Oct 24, 2013·Inorganic Chemistry·Elden P SwindellThomas V O'Halloran

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Apoptotic Caspases

Apoptotic caspases belong to the protease enzyme family and are known to play an essential role in inflammation and programmed cell death. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis